News

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education.

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency.

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Ophthalmologists report that dry eye syndrome, myopia progression and other ocular pathologies have increased, especially among paediatric patient groups

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

Personalizing treatment options and setting realistic expectations are crucial.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency

The company specializes in advanced modality antibody drugs.

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema.

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

In the European Union and the United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 was set by the organization.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Social determinants of health challenge our existing expectations

Patients with GCA, an autoimmune disease, are at risk for sudden vision loss which can be permanent

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.

Good safety profile and “meaningful improvement” in vision in Leber congenital amaurosis patient.

BRIMOCHOL PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of focus and sharpen near and distant impact.

Following Phase 3 pivotal trial BRIO-II, Tenpoint Therapeutics said they hope to launch BRIMOCHOL PF in 2026